Hasil Pencarian  ::  Simpan CSV :: Kembali

"Latar belakang: Infeksi virus dengue masih menjadi masalah di negara tropis seperti Indonesia. Infeksi virus dengue menyebabkan mortalitas dan morbiditas yang tinggi. Belum ada obat ataupun vaksin yang telah disetujui penggunaannya dan tersedia di dunia untuk penyakit infeksi dengue. Pencegahan infeksi dengue masih terbatas pada pengendalian vektor nyamuk Aedes aegypti. Keempat serotipe virus dengue beredar di Indonesia. Dua genotipe dari virus dengue tipe 1 (DENV-1) yaitu genotipe I dan IV lebih dominan bersirkulasi di Indonesia. Pada tahun 2012, kami mengembangkan kandidat vaksin DNA DENV-1 pUMVC RDS 59/09. Tujuan penelitian ini untuk mengetahui kadar antibodi anti-membran dan envelop DENV-1 yang dihasilkan mencit ddY setelah imunisasi sebanyak tiga kali dengan pUMVC RDS 59/09 dan untuk mengetahui kemampuan antibodi tersebut dalam menetralkan beberapa genotipe DENV-1 yang diisolasi di Indonesia. Metode: Penelitian eksperimental ini dimulai dari perbanyakan pUMVC RDS 59/09 di sel E.coli untuk mendapatkan konsentrasi yang tinggi. Imunisasi dilakukan pada 12 mencit strain ddY dengan pUMVC RDS 59/09 25 μg/100 μl menggunakan needle-free injector, sebanyak tiga kali dengan interval waktu 3 minggu. Sebanyak 12 mencit disediakan sebagai kontrol yang tidak diimunisasi. Antibodi anti-membran dan envelop DENV-1 pada masing-masing serum mencit diperiksa dengan ELISA dan dibaca pada panjang gelombang 450 nm. Berikutnya, pooled serum mencit pasca imunisasi ke 3, digunakan untuk netralisasi 13 isolat DENV-1 dengan metode focus reduction neutralization test (FRNT). Fokus yang didapatkan dari FRNT diwarnai dengan tehnik imunoperoksidase dan dihitung secara manual. Hasil: Rerata nilai OD ELISA antibodi anti-membran dan envelop DENV-1 dari serum mencit kelompok imunisasi yang diambil sebelum imunisasi, pasca imunisasi 1, pasca imunisasi 2 dan pasca imunisasi 3 adalah 0,329;0,843;1,524 dan 1,598, secara berurutan. Terdapat peningkatan nilai OD ELISA antibodi anti-membran dan envelop DENV-1 dari pooled serum mencit kelompok imunisasi pasca imunisasi pertama, kedua dan ketiga dibandingkan dengan baseline. Titer FRNT antibodi anti-membran dan envelop DENV-1 dari pooled serum mencit pasca imunisasi 3 dan pooled serum mencit kontrol terhadap strain DV-1 RDS 59/09 adalah 1/320 dan < 1/10. Titer FRNT 13 isolat DENV-1 oleh antibodi anti-membran dan envelop DENV-1 dari pooled serum mencit pasca imunisasi 3 berkisar dari 1/320 sampai lebih dari 1/1280. Kesimpulan: Variasi genotipe DENV-1 tidak menyebabkan perbedaan titer antibodi netralisasi yang bermakna (p = 0,222), sehingga dapat diuraikan bahwa antibodi anti-membran dan envelop DENV-1 dapat menetralkan 13 isolat DENV-1 Indonesia yang diuji.

---

Introduction: Dengue virus infection is still a burden in tropical country such as Indonesia. Dengue virus infection causes high mortality and morbidity. No drugs or vaccines are approved and available in the world for this disease. Dengue prevention is still limited to vector control. Four dengue serotypes are circulated in Indonesia. Two genotypes of Dengue virus type 1 (DENV-1), namely genotypes I and IV are found predominantly in Indonesia. Previously in 2012, we constructed pUMVC RDS 59/09, the DENV-1 DNA vaccine candidate. The objective of this study is to assess antibody level produced in ddY strain mice after three times immunization with pUMVC RDS 59/09 and to assess the antibody ability to neutralize genotypes of DENV-1 isolated in Indonesia.

Methods: This experimental study was started with propagation of pUMVC RDS 59/09 in E. coli cells to produce high concentration of the DNA. Immunization was carried out with 25 μg/ 100 μl pUMVC RDS 59/09 by needle-free injector, three times in 3 weeks interval. Twelve mice were provided for control without immunization. Anti-DENV-1 membrane and envelope antibody of individual sera were examined by ELISA and absorbance value was measured by ELISA reader in 450 nm wave length. Further, pooled sera of 3rd immunization were used to neutralize 13 DENV-1 isolates by focus reduction neutralization test (FRNT) method. The focus obtained in FRNT was stained by immune-peroxides technique and counted manually.

Results: ELISA OD value mean of anti-DENV-1 membrane and envelope antibody in individual ddY mice sera of immunized group before immunization, post first immunization, after second immunization and post third immunization were 0.329; 0.843; 1.524 and 1.598, respectively. An increase in ELISA OD value of anti-DENV-1 membrane and envelope antibody in ddY mice pooled sera of immunized group after first, second and third immunization compared to baseline was observed. FRNT titre of anti-DENV-1 membrane and envelope antibody from third immunization pooled sera compared to control mice pooled sera in RDS 59/09 isolate neutralization was 1/320 compared to < 1/10. Neutralization titre of 13 DENV-1 isolates by anti-DENV-1 membrane and envelope antibody from third immunization pooled sera ranged from 1/320 to more than 1/1280.

Conclussions: DENV-1 genotype variation did not lead to significant neutralization antibody titre difference (p = 0,222), so it can be explained that anti-DENV-1 membrane and envelope antibody was able to neutralize 13 strains of Indonesia DENV-1 isolates examined."

"[Latar belakang:Infeksi virus dengue masih menjadi masalah di negara tropis seperti Indonesia. Infeksi virus dengue menyebabkan mortalitas dan morbiditas yang tinggi. Belum ada obat ataupun vaksin yang telah disetujui penggunaannya dan tersedia di dunia untuk penyakit infeksi dengue. Pencegahan infeksi dengue masih terbatas pada pengendalian vektor nyamuk Aedes aegypti. Keempat serotipe virus dengue beredar di Indonesia. Dua genotipe dari virus dengue tipe 1 (DENV-1) yaitu genotipe I dan IV lebih dominan bersirkulasi di Indonesia. Pada tahun 2012, kami mengembangkan kandidat vaksin DNA DENV-1 pUMVC RDS 59/09. Tujuan penelitian ini untuk mengetahui kadar antibodi anti-membran dan envelop DENV-1 yang dihasilkan mencit ddY setelah imunisasi sebanyak tiga kali dengan pUMVC RDS 59/09 dan untuk mengetahui kemampuan antibodi tersebut dalam menetralkan beberapa genotipe DENV-1 yang diisolasi di Indonesia.Metode:Penelitian eksperimental ini dimulai dari perbanyakan pUMVC RDS 59/09 di sel E.coli untuk mendapatkan konsentrasi yang tinggi. Imunisasi dilakukan pada 12 mencit strain ddY dengan pUMVC RDS 59/09 25 µg/100 µl menggunakan needle-free injector, sebanyak tiga kali dengan interval waktu 3 minggu. Sebanyak 12 mencit disediakan sebagai kontrol yang tidak diimunisasi. Antibodi anti-membran dan envelop DENV-1 pada masing-masing serum mencit diperiksa dengan ELISA dan dibaca pada panjang gelombang 450 nm. Berikutnya, pooled serum mencit pasca imunisasi ke 3, digunakan untuk netralisasi 13 isolat DENV-1 dengan metode focus reduction neutralization test (FRNT). Fokus yang didapatkan dari FRNT diwarnai dengan tehnik imunoperoksidase dan dihitung secara manual.Hasil:Rerata nilai OD ELISA antibodi anti-membran dan envelop DENV-1 dari serum mencit kelompok imunisasi yang diambil sebelum imunisasi, pasca imunisasi 1, pasca imunisasi 2 dan pasca imunisasi 3 adalah 0,329;0,843;1,524 dan 1,598, secara berurutan. Terdapat peningkatan nilai OD ELISA antibodi anti-membran dan envelop DENV-1 dari pooled serum mencit kelompok imunisasi pasca imunisasi pertama, kedua dan ketiga dibandingkan dengan baseline. Titer FRNT antibodi anti-membran dan envelop DENV-1 dari pooled serum mencit pasca imunisasi 3 dan pooled serum mencit kontrol terhadap strain DV-1 RDS 59/09 adalah 1/320 dan < 1/10. Titer FRNT 13 isolat DENV-1 oleh antibodi anti-membran dan envelop DENV-1 dari pooled serum mencit pasca imunisasi 3 berkisar dari 1/320 sampai lebih dari 1/1280.Kesimpulan:Variasi genotipe DENV-1 tidak menyebabkan perbedaan titer antibodi netralisasi yang bermakna (p = 0,222), sehingga dapat diuraikan bahwa antibodi anti-membran dan envelop DENV-1 dapat menetralkan 13 isolat DENV-1 Indonesia yang diuji., Introduction:Dengue virus infection is still a burden in tropical country such as Indonesia. Dengue virus infection causes high mortality and morbidity. No drugs or vaccines are approved and available in the world for this disease. Dengue prevention is still limited to vector control. Four dengue serotypes are circulated in Indonesia. Two genotypes of Dengue virus type 1 (DENV-1), namely genotypes I and IV are found predominantly in Indonesia. Previously in 2012, we constructed pUMVC RDS 59/09, the DENV-1 DNA vaccine candidate. The objective of this study is to assess antibody level produced in ddY strain mice after three times immunization with pUMVC RDS 59/09 and to assess the antibody ability to neutralize genotypes of DENV-1 isolated in Indonesia. Methods:This experimental study was started with propagation of pUMVC RDS 59/09 in E. coli cells to produce high concentration of the DNA. Immunization was carried out with 25 µg/ 100 µl pUMVC RDS 59/09 by needle-free injector, three times in 3 weeks interval. Twelve mice were provided for control without immunization. Anti-DENV-1 membrane and envelope antibody of individual sera were examined by ELISA and absorbance value was measured by ELISA reader in 450 nm wave length. Further, pooled sera of 3rd immunization were used to neutralize 13 DENV-1 isolates by focus reduction neutralization test (FRNT) method. The focus obtained in FRNT was stained by immune-peroxides technique and counted manually. Results:ELISA OD value mean of anti-DENV-1 membrane and envelope antibody in individual ddY mice sera of immunized group before immunization, post first immunization, after second immunization and post third immunization were 0.329; 0.843; 1.524 and 1.598, respectively. An increase in ELISA OD value of anti-DENV-1 membrane and envelope antibody in ddY mice pooled sera of immunized group after first, second and third immunization compared to baseline was observed. FRNT titre of anti-DENV-1 membrane and envelope antibody from third immunization pooled sera compared to control mice pooled sera in RDS 59/09 isolate neutralization was 1/320 compared to < 1/10. Neutralization titre of 13 DENV-1 isolates by anti-DENV-1 membrane and envelope antibody from third immunization pooled sera ranged from 1/320 to more than 1/1280.Conclussions:DENV-1 genotype variation did not lead to significant neutralization antibody titre difference (p = 0,222), so it can be explained that anti-DENV-1 membrane and envelope antibody was able to neutralize 13 strains of Indonesia DENV-1 isolates examined.]"

"[ABSTRAKPendahuluan: Infeksi dengue merupakan salah satu penyakit endemik di daerah tropis dan subtropis yang disebabkan oleh virus dengue (DENV). Hingga saat ini belum ada antiviral yang efektif untuk infeksi dengue. Penyebaran dan sirkulasi serotipe DENV berfariasi di setiap lokasi geografi, hal ini menyulitkan dalam melakukan evaluasi vaksin DENV. Oleh karena itu perlu dikembangkan kandidat vaksin DENV menggunakan strain Indonesia supaya dapat memberikan proteksi maksimal. Pada peneltian ini dikembangkan kandidat vaksin DNA tetravalen DENV berbasis gen prM-E DENV strain Indonesia.Metode: Konstruksi plasmid rekombinan kandidat vaksi dilakukan dengan cara menyisipkan gen prM-E setiap serotipe DENV ke dalam vektor pUMVC4a. Gen prM-E DENV merupakan strain Indonesia, yang diamplifikasi dari serum pasien yang terinfeksi dengan virus ini. Kemampuan plasmid rekombinan mengekspresikan protein prM-E DENV diuji di sel mamalia. Kemampuan kandidat vaksin menginduksi respon imun humoral dievaluasi secara monovalen dan tetravalen di mencit jenis ddY. Titer IgG anti dengue diperiksa menggunakan teknik ELISA, sedangkan titer antibodi netralisasi di tentukan dengan uji FRNT. Proteksi vaksin terhadap mencit yang diimunisasi dievaluasi dengan melakukan uji tantang menggunakan sel K562 yang diinfeksi DENV-2. Viremi virus di tentukan dengan menggunakan teknik foccus assay.Hasil: Konstruksi plasmid rekombinan kandidat vaksin DENV-1 dan DENV-3 sudah berhasil dilakukan. Plasmid dapat mengekspresikan protein prM-E DENV di sel mamalia, namun karakteristik dan kinetik protein masih belum dapat diketahui dengan jelas. Keempat kandidat vaksin DNA yang sedang dikembangkan dapat menginduksi respon imun, baik secara monovalen maupun tetravalen. Imunisasi secara tetravalen dapat memberikan proteksi pada mencit yang diuji tantang dengan sel K562 yang diinfeksi dengan DENV-2.;

---

ABSTRACTIntroduction: Dengue infections are caused by dengue viruses (DENV) and are endemic in tropical and subtropical regions. At present, there is no effective antiviral treatment for dengue infection. Distribution and circulation of DENV serotypes varies by geographic location, it is difficult to evaluate DENV vaccine. Therefore, it is necessary to develop a vaccine candidate DENV using Indonesian strains in order to provide maximum protection. However, in this study, we constructed a recombinant plasmid-based prM-E gene from the Indonesia strain as a DENV DNA vaccine candidate.Methode: The recombinant plasmid was prepared by inserting the prM-E gene from each DENV serotypes into the plasmid backbone pUMVC4a. prM-E gene an Indonesia strain, which was amplified from patient sera infected with DENV. The ability of the recombinant plasmid expressing the prM-E DENV protein tested in mammalian cells. The ability of candidate vaccines induce humoral immune responses were evaluated monovalent and tetravalent in ddY mice. IgG titers of anti-dengue examined using ELISA technique, while neutralizing antibody titers determined with FRNT test. Vaccine protection against the immunized mice was evaluated by conducting challenge test using K562 cells infected by DENV-2. Viremia was determined by using the foccus assay.Result: Construction of recombinant plasmid vaccine candidate DENV-1 and DENV-3 was successfully performed. Plasmids can express prM-E DENV proteins in mammalian cells, but the characteristics and kinetics of protein still can not clearly known. Fourth DNA vaccine candidate that is being developed to induce an immune response, either monovalent or tetravalent. Tetravalent immunization may provide protection in mice challenged tested with K562 cells infected with DENV-2.;Introduction: Dengue infections are caused by dengue viruses (DENV) and are endemic in tropical and subtropical regions. At present, there is no effective antiviral treatment for dengue infection. Distribution and circulation of DENV serotypes varies by geographic location, it is difficult to evaluate DENV vaccine. Therefore, it is necessary to develop a vaccine candidate DENV using Indonesian strains in order to provide maximum protection. However, in this study, we constructed a recombinant plasmid-based prM-E gene from the Indonesia strain as a DENV DNA vaccine candidate.Methode: The recombinant plasmid was prepared by inserting the prM-E gene from each DENV serotypes into the plasmid backbone pUMVC4a. prM-E gene an Indonesia strain, which was amplified from patient sera infected with DENV. The ability of the recombinant plasmid expressing the prM-E DENV protein tested in mammalian cells. The ability of candidate vaccines induce humoral immune responses were evaluated monovalent and tetravalent in ddY mice. IgG titers of anti-dengue examined using ELISA technique, while neutralizing antibody titers determined with FRNT test. Vaccine protection against the immunized mice was evaluated by conducting challenge test using K562 cells infected by DENV-2. Viremia was determined by using the foccus assay.Result: Construction of recombinant plasmid vaccine candidate DENV-1 and DENV-3 was successfully performed. Plasmids can express prM-E DENV proteins in mammalian cells, but the characteristics and kinetics of protein still can not clearly known. Fourth DNA vaccine candidate that is being developed to induce an immune response, either monovalent or tetravalent. Tetravalent immunization may provide protection in mice challenged tested with K562 cells infected with DENV-2., Introduction: Dengue infections are caused by dengue viruses (DENV) and are endemic in tropical and subtropical regions. At present, there is no effective antiviral treatment for dengue infection. Distribution and circulation of DENV serotypes varies by geographic location, it is difficult to evaluate DENV vaccine. Therefore, it is necessary to develop a vaccine candidate DENV using Indonesian strains in order to provide maximum protection. However, in this study, we constructed a recombinant plasmid-based prM-E gene from the Indonesia strain as a DENV DNA vaccine candidate.Methode: The recombinant plasmid was prepared by inserting the prM-E gene from each DENV serotypes into the plasmid backbone pUMVC4a. prM-E gene an Indonesia strain, which was amplified from patient sera infected with DENV. The ability of the recombinant plasmid expressing the prM-E DENV protein tested in mammalian cells. The ability of candidate vaccines induce humoral immune responses were evaluated monovalent and tetravalent in ddY mice. IgG titers of anti-dengue examined using ELISA technique, while neutralizing antibody titers determined with FRNT test. Vaccine protection against the immunized mice was evaluated by conducting challenge test using K562 cells infected by DENV-2. Viremia was determined by using the foccus assay.Result: Construction of recombinant plasmid vaccine candidate DENV-1 and DENV-3 was successfully performed. Plasmids can express prM-E DENV proteins in mammalian cells, but the characteristics and kinetics of protein still can not clearly known. Fourth DNA vaccine candidate that is being developed to induce an immune response, either monovalent or tetravalent. Tetravalent immunization may provide protection in mice challenged tested with K562 cells infected with DENV-2.]"

"ABSTRAKInfeksi yang disebabkan oleh virus dengue telah banyak dilaporkan di negara tropis dan subtropis. Virus dengue terdiri dari 4 serotipe yaitu dengue 1-4. Hingga saat ini belum tersedia vaksin yang berlisensi untuk mencegah terjadinya infeksi dengue. Pada penelitian ini dikonstruksi vaksin DNA yang mengkode gen prM-E dan prM-E-NS1del virus dengue 2 strain Indonesia yang akan dijadikan sebagai kandidat vaksin dengue. Hasil penelitian berhasil mendapatkan 9 plasmid rekombinan pUMDE2 yang membawa gen sisipan prM-E dan telah dikonfirmasi dengan melakukan PCR koloni dan restriksi plasmid. Dari hasil sekuensing plasmid pUMDE2 koloni no. 11 ditemukan 19 mutasi asam amino pada gen prM-E, sepuluh mutasi pada gen prM dan sembilan mutasi pada gen E. Mutasi protein prM N29D dan N52K serta protein E V164I dan S390N terletak pada daerah epitop pengenalan sel B. Transfeksi plasmid pUMDE2 dilakukan pada sel Chinese Hamster Ovary (CHO)-K1 dan menunjukkan adanya ekspresi protein prM-E rekombinan berdasarkan uji imunostaining dan ELISA. Hasil ELISA menunjukkan bahwa protein ditemukan pada sel yang ditransfeksi. Sedangkan, plasmid rekombinan yang membawa gen prM-E-NS1del tidak berhasil dikonstruksi. Plasmid pUMDE2 dapat dikembangkan menjadi kandidat vaksin DNA.

---

ABSTRACT

Infection by dengue virus were reported in tropical and subtropical area. Dengue virus (DENV) consist of 4 serotype, DENV-1 to DENV-4. There is no licensed vaccine available for dengue infection. In this research, we construct DNA vaccine encode prM-E and prM-E-NS1del genes of dengue virus serotype 2 for vaccine development. Nine recombinant plasmids that encode prM-E genes (pUMDE2), were successfully obtained. Recombinant plasmids were confirmed by PCR colony and restriction enzyme analysis. Colony of pUMDE2 no. 11 was sequenced and total 19 amino acid mutations were founds, 10 mutations in prM and 9 mutations in E protein. prM mutations N29D and N52K, E mutations of V164I and S390N were found in B cell epitopes. Transfection pUMDE2 plasmid was done to Chineese Hamster Ovary (CHO)-K1 and showed that recombinant protein prM-E was successfully expressed by immunostaining assay and ELISA. Results showed that the protein was mainly found in cell fraction. However, recombinant plasmid that encode prM-E-NS1del were failed to be constructed. pUMDE2 could be developed for vaccine candidate."

"ABSTRAKLatar Belakang : Penyakit demam dengue dan demam berdarah dengue yang disebabkan oleh virus dengue masih menjadi masalah kesehatan di dunia. Hingga saat ini pengobatan spesifik serta vaksin untuk infeksi dengue belum tersedia, dan berbagai strategi pembuatan vaksin sedang dikembangkan oleh berbagai pihak. Sebagai salah satu negara endemis infeksi dengue, Indonesia juga perlu melakukan pengembangan vaksin dengue dengan menggunakan strain virus yang berasal dari Indonesia. Pada penelitian ini akan dikembangkan kandidat vaksin DNA rekombinan dengan gen insersi Premembran dan Envelope virus dengue tipe 2 sebagai bagian dari pengembangan vaksin dengue tetravalen di Indonesia.Metode : Plasmid DNA rekombinan dirancang mengandung gen premembran dan envelope dari virus dengue tipe 2 isolat Indonesia. Fragmen DNA diinsersi ke dalam vektor plasmid pUMVC4a serta ditransformasi ke dalam sel E.coli DH5-α. Klon plasmid yang didapat dikonfirmasi dengan metode PCR, enzim restriksi dan sekuensing. Ekspresi protein dari plasmid diuji melalui metode transfeksi pada sel Vero. Selanjutnya plasmid disuntikkan pada mencit jenis Balb/C sebanyak 3 kali dengan interval 3 minggu pada daerah intramuskular. Penyuntikan menggunakan 2 metode : suntikan intramuskular dengan jarum (IM) dan suntikan dengan menggunakan alat needle-free injector (NFI) dengan menggunakan 2 macam dosis plasmid, yaitu 25 μg dan 100 μg DNA. Pemeriksaan antibodi dilakukan dengan metode ELISA dan PRNT. Setelah fase imunisasi selesai, dilakukan uji tantang dengan menyuntikkan 2,5 x 105 PFU/ml DENV-2 secara intraperitoneal pada beberapa kelompok mencit untuk melihat pembentukan sel B memori. Data antibodi yang diperoleh dianalisis secara deskriptif dan analitik.Hasil : Plasmid rekombinan pUMD2 telah berhasil diperoleh. Transfeksi pada sel Vero menunjukkan adanya ekspresi protein intra dan ekstraselular melalui pemeriksaan imunostaining dan ELISA. Melalui pemeriksaan ELISA, antibodi terdeteksi hanya pada kelompok penyuntikan NFI (p<0,005). Titer antibodi tertinggi dijumpai pada kelompok penyuntikan dengan NFI dosis 100 μg , kemudian NFI 25 μg dengan perbedaan yang tidak bermakna (p>0,005) antara kedua kelompok tersebut. Melalui PRNT 70% ditemukan bahwa antibodi netralisasi terhadap DENV-2 terbentuk pada mencit yang diberi imunisasi dengan metode NFI, sedangkan pada kelompok IM titernya tidak terdeteksi (<1/10). Titer antibodi terbaik diperoleh pada kelompok penyuntikan NFI dosis 100 ug yaitu 1/80-1/160. Titer hari ke-4 dan 8 setelah penyuntikan 2,5 x 105 PFU/ml virus pada kelompok yang diimunisasi secara IM dan NFI mengalami peningkatan. Sebaliknya, pada kelompok yang tidak diberi virus tidak terdapat peningkatan titer netralisasi. Hal ini menunjukkan adanya pembentukan sel B memori dari imunisasi yang diberikan.Kesimpulan : Pembuatan plasmid rekombinan dengan gen insersi pre-M dan E DENV2 strain DS18/09 telah berhasil dilakukan. Terdapat respon antibodi netralisasi dan anamnestik dari mencit yang diberi imunisasi secara NFI, namun imunisasi secara IM hanya menunjukkan respon antibodi anamnestik dari sel memori. Plasmid DNA rekombinan ini memiliki potensi sebagai kandidat vaksin DNA terhadap virus dengue tipe 2. Perlu dilakukan penelitian selanjutnya berupa rancangan vaksin tetravalen dalam upaya pengembangan vaksin dengue secara menyeluruh.

---

ABSTRACTIntroduction : Dengue fever and dengue haemorrhagic fever caused by dengue virus is still a major health problem. There are four types of Dengue virus which antigenically distinguished : DEN-1, DEN-2, DEN-3, DEN-4. Currently, no specific treatment for Dengue infection and no vaccine are available, and various strategies have been used to develop dengue vaccine. Indonesia as one of dengue-endemic country has to attempt dengue vaccine development particularly using Indonesian virus strain. In this study, recombinant DNA vaccine candidate using DENV-2 pre-membrane and envelope genes was constructed as a part of dengue tetravalent vaccine development in Indonesia.Methods : The recombinant plasmid consisting pre-membrane and envelope genes from DENV-2 Indonsia isolate was constructed. DNA fragment were inserted to pUMVC4a plasmid vector and then transformed to E. Coli DH5-α. The construction was confirmed using PCR, restriction enzyme and sequencing. Protein expressions of preM and E were determined by transfection into Vero cells. Group of Balb/C mice were injected with amount of plasmid via intra muscular route. The injection was conducted using 2 delivery methods : conventional syringe-needle (IM) and needle-free injector (NFI) device. Doses of plasmid that being compared are 25 μg and 100 μg. Mice were immunized with plasmid 3 times with 3 weeks interval. Antibody titre were determined by ELISA and PRNT. After immunization phase, part group of mice challanged with 2,5 x 105 PFU/ml DENV-2 intra peritoneally to confirm wether immunization induced memory cells. Antibody data were interpretated by descriptive and analytic methodsResults : The recombinant plasmid pUMD2 has been constructed. Confirmation of gene secuence showed no mutation at the clone. Vero cells-81 transfected with pUMD2 expressed prM and E as determined by immunofluorescence staining as intracellular protein and by ELISA to detect extracellular protein. In ELISA results, antibody was detected only in NFI group (p<0,005). Highest antibody titre was found in NFI group with dose 100 μg followed by dose 25 μg. However, antibody titre by ELISA between NFI group dose 100 μg and 25 μg were not statistically significant (p>0,005). Neutralizing antibody by PRNT 70% showed concordant result compared to ELISA. Neutralizing titre to DENV-2 was developed in NFI group, but it was not detectable in IM group of mice (<1/10). The highest titre of neutralization achieved by 100 μg, NFI group whose titer 1/80-1/160. Immunized mice in all groups raised greater neutralizing antibody titers on days 4 and 8 after challange with 2,5 x 105 PFU/ml of DS 18/09 of dengue type 2 virus. Compared to immunized mice that were not challanged which developed no increasing neutralizing titre, it indicated that immunization could produced memory B cell responses.Conclusions : Recombinant plasmid as a candidate for dengue DNA vaccine has been constructed. The plasmid expressed premembrane and envelope proteins in Vero cells. Immunogenicity test from the plasmid DNA demonstrated neutralizing antibody responses and anamnestic responses in mice which immunized only by NFI method. IM injection method only showed anamnestic antibody responses. Overall, this DNA plasmid has a potency to be used as a candidate for DNA vacine against dengue virus type-2. Study for designing tetravalent vaccine model is necessary as a part in vaccine dengue development."

"Indonesia merupakan negara dengan jumlah kasus dengue terbanyak dan terparah di Asia Tenggara Studi filogenetik virus dengue DENV diperlukan sebagai dasar pengembangan struktur vaksin yang cocok Meskipun demikian data sekuens DENV masih terbatas Penelitian ini bertujuan menganalisis sekuens dan filogenetik keseluruhan gen envelope DENV 1 dibandingkan dengan domain III saja Data didapatkan dari GenBank dan Laboratorium Mikrobiologi Fakultas Kedokteran Universitas Indonesia berupa whole genome DENV 1 sebanyak 30 sekuens yang diolah dengan Genetyx 5 1 Hasil analisis nukleotida gen envelope DENV 1 menunjukan strain Indonesia termasuk genotipe I dan IV Sedangkan analisis nukleotida dengan hanya domain III menunjukan adanya perbedaan cluster antar strain namun tetap dalam genotipe yang sama Dengan demikian studi filogenetik penentuan genotipe dapat dilakukan dengan hanya menggunakan domain III saja Analisis homologi asam amino domain III menunjukan epitope utama dilestarikan dan dapat menjadi landasan penting dalam pembuatan vaksin dengue berbasis domain III

---

Phylogenetic study of dengue virus DENV is required as a basis to develop a suitable structure for vaccine development Nonetheless DENV sequence data is limited This study aims to analyze and compare the sequence and phylogenetic of DENV 1 envelope gene with domain III The data is obtained from GenBank and Laboratory of Microbiology Faculty of Medicine Universitas Indonesia Thirty sequences of DENV 1 whole genome were processed using Genetyx 5 1 Analysis using DENV 1 envelope nucleotide showed that strain Indonesia has genotype I and IV Analysis using only the nucleotide of domain III showed the same genotype with difference of clusters between strains Thus phylogenetic studies determining the genotype can be done using domain III alone Homology analysis of amino acid of domain III showed that the main epitope is well reserved This finding can be an important cornerstone in the development of domain III based dengue vaccine."

"[ABSTRAKDemam berdarah dengue (DBD) merupakan penyakit yang disebabkan karenainfeksi virus dengue (DENV), yang banyak ditemukan di Indonesia. Belum adaterapi yang spesifik dalam pengobatan DBD. Upaya pengembangan vaksindengue yang efektif sangat diperlukan. Pada penelitian ini dilakukan analisaimunogenisitas kandidat vaksin DNA prM-E dengue serotipe 2 (pUMD2.kl.20)dengan menganalisis sel T CD4, sel T CD8, IFN-γ dan TNF-α. pada sel U937 danPBMC secara in vitro, bertujuan untuk mengetahui respon imun ketika vaksindiinjeksikan ke dalam tubuh manusia. Dasar penelitian ini adalah sel U937ditransfeksi dengan pUMD2.kl.20 menggunakan lipofectamin. Sel U937 akanberperan sebagai APCs yang akan mengekspresikan protein prM-E DENV-2 danmempresentasikan protein tersebut melalui molekul MHC class I dan MHC classII kepada Peripheral Blood Mononuclear Cell (PBMC) manusia. Tahapan kerjayang dilakukan dalam penelitian ini terdiri dari: (a) kultur galur sel U937, (b)transfeksi sel U937 dengan pUMD2.kl.20, (c) transfeksi sel U937 dengan plasmids(pUMVC), (d) infeksi sel U937 dengan DENV-2 strain DS.18/09, (e) pewarnaandan pengamatan hasil pewarnaan menggunakan alat semi flowcytometri (TALI).pUMD2.kl.20 mengaktivasi sel T CD4 dan sel T CD8 untuk berploriferasi. Hasilpenelitian ini menunjukkan bahwa konsentrasi sel T CD8 lebih tinggi darikonsentrasi sel T CD4 dan konsentrasi sel positif yang mensekresikan IFNγ lebihtinggi dari konsentrasi sel positif yang mensekresikan TNFα. Kondisi optimal dariaktivasi sel T CD4 oleh pUMD2.kl.20 adalah 24 jam setelah penambahan PBMCsetelah transfeksi (8,53x10⁴sel/ml), untuk sel T CD8 adalah 24 jam setelahpenambahan PBMC setelah transfeksi (49,4x10⁴ sel/ml). Kondisi optimal dariaktivasi sel+ yang mensekresikan IFNγ oleh pUMD2.kl.20 adalah 24 jam setelahpenambahan PBMC 48 jam setelah transfeksi (9,86x10⁴ sel/ml), dan untuk sel+yang mensekresikan TNFα adalah 2 jam setelah penambahan PBMC 48 jamsetelah transfeksi (2,1x10⁴ sel/ml). Dari penelitian ini dapat disimpulkan bahwapUMD2.kl.20 bersifat imunogenik.

---

ABSTRACTDengue hemorrhagic fever (DHF) is a disease caused by infection with denguevirus (DENV), which is found in Indonesia. There is no specific therapy in thetreatment of DHF. An effort to develop an effective dengue vaccine is needed. Inthis research, analysis of the immunogenicity of the DNA vaccine candidate prMEdengue serotype 2 (pUMD2.kl.20) by analyzing the CD4 T cells, CD8 T cells,IFN-γ and TNF-α in U937 cells and PBMC in vitro, aims to determine theimmune response when the vaccine is injected into the human body. This researchapproach is based on transfection of U937 cells with pUMD2.kl.20 usinglipofectamin. U937 cells acts as APCs which will express the protein prM-EDENV-2 and presenting these proteins through the MHC class I and MHC class IImolecule to the Peripheral Blood Mononuclear Cell (PBMC) of human body.Stages of the work in this study consisted of: (a) culture cell line U937, (b)transfection of U937 cells with pUMD2.kl.20, (c) transfection of U937 cells withplasmid (pUMVC), (d) infection of U937 cells with DENV-2 strains DS.18/09,(e) staining and observation results of staining using a semi-flow cytometri(TALI). pUMD2.kl.20 activate CD4 T cells and CD8 T cells to proliferate. CD8 Tcells concentration higher than the concentration of CD4 T cells and the secretionof INFγ-positive cells concentration higher than the concentration of the secretionof TNFα-positive cells. Optimal condition of CD4 T cells activation bypUMD2.kl.20 is 24 hours after the addition of PBMC after transfection (8,53x10⁴cells/ml), for CD8 T cells was 24 hours after the addition of PBMC aftertransfection (49,4x10⁴ cells/ml). Optimal conditions secretion of IFNγ-positivecells were activated by pUMD2.kl.20 is 24 hours after the addition of PBMC 48hours after transfection (9,86x10⁴ cells/ml), and for the secretion of TNFα-positive cells were activated by pUMD2.kl.20 is 2 hours after the addition ofPBMC 48 hours after transfection (2,1x10⁴ cells/ml). From this study it can beconcluded that the pUMD2.kl.20 immunogenic, Dengue hemorrhagic fever (DHF) is a disease caused by infection with denguevirus (DENV), which is found in Indonesia. There is no specific therapy in thetreatment of DHF. An effort to develop an effective dengue vaccine is needed. Inthis research, analysis of the immunogenicity of the DNA vaccine candidate prMEdengue serotype 2 (pUMD2.kl.20) by analyzing the CD4 T cells, CD8 T cells,IFN-γ and TNF-α in U937 cells and PBMC in vitro, aims to determine theimmune response when the vaccine is injected into the human body. This researchapproach is based on transfection of U937 cells with pUMD2.kl.20 usinglipofectamin. U937 cells acts as APCs which will express the protein prM-EDENV-2 and presenting these proteins through the MHC class I and MHC class IImolecule to the Peripheral Blood Mononuclear Cell (PBMC) of human body.Stages of the work in this study consisted of: (a) culture cell line U937, (b)transfection of U937 cells with pUMD2.kl.20, (c) transfection of U937 cells withplasmid (pUMVC), (d) infection of U937 cells with DENV-2 strains DS.18/09,(e) staining and observation results of staining using a semi-flow cytometri(TALI). pUMD2.kl.20 activate CD4 T cells and CD8 T cells to proliferate. CD8 Tcells concentration higher than the concentration of CD4 T cells and the secretionof INFγ-positive cells concentration higher than the concentration of the secretionof TNFα-positive cells. Optimal condition of CD4 T cells activation bypUMD2.kl.20 is 24 hours after the addition of PBMC after transfection (8,53x10⁴cells/ml), for CD8 T cells was 24 hours after the addition of PBMC aftertransfection (49,4x10⁴ cells/ml). Optimal conditions secretion of IFNγ-positivecells were activated by pUMD2.kl.20 is 24 hours after the addition of PBMC 48hours after transfection (9,86x10⁴ cells/ml), and for the secretion of TNFα-positive cells were activated by pUMD2.kl.20 is 2 hours after the addition ofPBMC 48 hours after transfection (2,1x10⁴ cells/ml). From this study it can beconcluded that the pUMD2.kl.20 immunogenic]"

" ABSTRAK Dengue Hemorrhagic Fever (DHF) are viral diseases transmitted by mosquito vector spreads fastest in the world. Cause of dengue fever are RNA virus family Flaviviridae called dengue virus (DENV). DENV genome encodes three structural proteins, capsid (C), membrane proteins (prM), envelope protein (E) and seven nonstuktural protein NS1, NS2a, NS2b, NS3, NS4a, NS4B, and NS5. NS3 protein contains many epitopes that can be recognized by the humoral and cellular immune system. Therefore NS3 protein is a potential target for development of dengue vaccines. This study begins by sequencing NS3 gene DENV-4 IDS 96/10. Phylogenetic analysis and epitope analysis were done from the result of sequencing. Phylogenetic analysis showed IDS 96/10 are in one clade with strains isolated rom China (2010), Singapore (2010) and Thailand (2000). NS3 gene DENV-4 IDS 96/10 contained epitopes recognized by CD4+ T cell that is epitope # 3 on the position of amino acids (213-227), # 9A (243-257), # 4 (251-265), # 5 (258-272), # 6 (266-280), # 7 (273-287) which has the same amino acid sequence comparison between strains. At position # 8 epitope (281-295) there are variation of amino acid sequence . Amino acids at positions 500-508 is recognized by CD8 + lymphocytes have the same sequence between strains were compared, and the amino acids at positions 526-531 which recognised by has the same amino acid sequence comparison between strains. Recognition of these epitopes by T lymphocytes and B lymphocytes can be the basis for the development of vaccines, especially vaccines for the Indonesian strain. Cloning of NS3 gene IDS 96/10 were done by using 3 strategies, digestion sticky end of vector and insert, digestion blunt end of vector and digestion blunt end vector then didefosforilation using CIAP. Three of these strategies have not been able to produce a recombinant plasmid pUMVD-4aNS3. Further optimization needs to be done to obtain clones containing the recombinant plasmid.

---

ABSTRACTDemam Berdarah Dengue (DBD) adalah penyakit yang disebabkan virus dengan vektor nyamuk yang paling cepat menyebar di duniaGenom DENV terdiri dari tiga protein struktural yaitu capsid (C), protein membran (prM), dan protein envelop (E) serta tujuh gen protein nonstuktural yaitu NS1, NS2a, NS2b, NS3, NS4a,NS4b dan NS5. Protein NS3 mengandung epitop yang dapat dikenali oleh sistem imun humoral maupun selular. Oleh karena itu, protein NS3 merupakan target potensial bagi pengembangan vaksin dengue. Penelitian ini diawali dengan sekuensing pada gen NS3 DENV-4 IDS 96/10. Dari hasil sekuensing dilakukan analisis filogenetik dan analisis epitop. Analisis filogenetik menunjukkan gen NS3 IDS 96 /10 berada dalam satu clade dengan strain yang diisolasi dari Cina (2010), Singapore (2010) dan Thailand (2000). Pada gen NS3 DENV-4 IDS 96/10 terdapat epitop yang dapat dikenali oleh sel limfosit T CD4+ yaitu epitop #3 pada posisi asam amino (213-227) , #9A (243-257), #4 (251-265), #5 (258-272), # 6 (266-280), #7 (273-287) yang mempunyai urutan asam amino sama antar strain yang dibandingkan. Pada posisi epitop #8 (281-295) terdapatvariasi urutan asam amino. Asam amino pada posisi CD8+ mempunyai urutan yang sama antar strain yang dibandingkan,dan asam amino pada posisi 526-531 yang dikenali oleh limfosit B mempunyai urutan asam amino yang sama antar strain yang dibandingkan. Pengenalan epitop- epitop tersebut oleh limfosit T dan limfosit B menjadi dasar pengembangan vaksin khususnya vaksin yang khusus untuk strain Indonesia. Dilakukan pengklonaan gen NS3 IDS 96/10 dengan menggunakan 3 strategi, yaitu dengan digesti vektor dan insert dengan ujung sticky end, digesti vektor dengan ujung blunt end dan digesti vektor dengan ujung blunt end kemudian didefosforilasi menggunakan metode CIAP. Dengan ketiga strategi tersebut belum dapat menghasilkan plasmid rekombinan pUMVD-4aNS3. Perlu dilakukan optimasi lebih lanjut untuk mendapatkan klon yang berisi plasmid rekombinan.Demam Berdarah Dengue (DBD). Penyebab DBD adalahvirus RNA famili flaviviridae yang disebut virus dengue (DENV).500-508 dikenali oleh sellimfosit TCD8+ mempunyai urutan yang sama antar strain yang dibandingkan,dan asam amino pada posisi 526-531 yang dikenali oleh limfosit B mempunyai urutan asam amino yang sama antar strain yang dibandingkan. Pengenalan epitop- epitop tersebut oleh limfosit T dan limfosit B menjadi dasar pengembangan vaksin khususnya vaksin yang khusus untuk strain Indonesia. Dilakukan pengklonaan gen NS3 IDS 96/10 dengan menggunakan 3 strategi, yaitu dengan digesti vektor dan insert dengan ujung sticky end, digesti vektor dengan ujung blunt end dan digesti vektor dengan ujung blunt end kemudian didefosforilasi menggunakan metode CIAP. Dengan ketiga strategi tersebut belum dapat menghasilkan plasmid rekombinan pUMVD-4aNS3. Perlu dilakukan optimasi lebih lanjut untuk mendapatkan klon yang berisi plasmid rekombinan."

"Demam Dengue (DD) dan Demam Berdarah Dengue (DBD) adalah penyakit yang tersebar luas. Penelitian ini dilakukan untuk mengembangkan kandidat vaksin dengue nasional berbasis protein sub unit prM/E DEN-4. Protein prM/E adalah kompleks unik yang berperan penting dalam perakitan virus dan modulasi fusi. Penelitian telah dilakukan dengan metode Gateway cloning system untuk menklon gen prM/E dalam plasmid cloning pDONR221 kemudian dilakukan subkloning dan dipindahkan gen prM/E ke dalam plasmid eksperesi pET-55-DEST. Ekspresi protein prM/E dilakukan di dalam E.coli BL21 (DE3) dengan induksi Isoprophyl-β-D-thiogalactopyranoside (IPTG). Pendeteksian poliprotein Gag hasil ekspresi dilakukan dengan metode Sodium Dodecyl Sulphate Polyacrilamide Gel Electrophoresis (SDS-PAGE). Setelah protein prM/E berhasil dideteksi kemudian protein prM/E dipurifikasi dengan menggunakan metode immobilized metal affinity chromatography (IMAC) di bawah kondisi denaturasi. Hasil penelitian yaitu protein prM/E dapat diekspresikan dalam E.coli BL21 (DE3) dengan berat molekul ~75 kDa.

---

Dengue Fever is an infectious disease caused by one of the four serotypes of dengue virus (DENV). Until now, no licensed vaccines or antivirus is available commercially. Because of that, this research was aimed to develop candidate vaccine dengue based on protein subunit pre-membrane and Envelope (prM/E). Protein prM/E is a unique complex which has important role in virus assemblyand host cell entry. The recombinant protein development was done using Gateway cloning system. This was used to clone the prM/E gene into pDONR221 plasmid. The cloned gene was then transferred into pET-55-DEST expression plasmid. Expression of protein prM/E was perfomed in E. coli BL21 (DE3) with inducer Isoprophyl-β-D-thiogalactopyranoside (IPTG). Sodium Dodecyl Sulphate Polyacrilamide Gel Electrophoresis (SDS-PAGE) method was used to detect the expressed prM/E protein. Upon detection of prM/E protein with SDS-PAGE, the recombinant protein was purified by using immobilized metal affinity chromatography (IMAC) method under denature condition. Using these methods, the prM/E protein was successfully expressed in E.coli BL21 (DE3) with a molecular weight ~75 kDa."

"Infeksi dengue DENV adalah penyakit yang diperantarai nyamuk yang manifestasinya dapat mengarah pada dengue hemorrhagic fever DHF dan/atau dengue shock syndrome DSS yang dapat mengakibatkan kematian. Di Indonesia, DHF sudah endemis dan menjadi penyakit yang terjadi sepanjang tahun. Protein non struktural-1 NS1 dari DENV diketahui merupakan biomarker dalam diagnosis dengue karena protein ini bersirkulasi dalam darah selama fase akut penyakit. Penelitian ini bertujuan untuk mengembangkan antibodi monoklonal mAb untuk mendeteksi antigen NS1 dari DENV serotipe 3 DENV3. Sel hibridoma penghasil mAb diperoleh dengan memfusikan sel B dari mencit yang diimunisasi dengan antigen NS1 yang diekspresikan pada sel CHO-K1 dengan sel PAI myeloma. Seleksi hibridoma dengan ELISA indirect diperoleh 16 klona yang berpotensi menghasilkan antibodi anti-NS1. Tujuh klona terbaik dipilih untuk dikarakterisasi dengan metode IFA terhadap antigen rekombinan NS1 dan hasilnya 6 klona positif menunjukkan reaksi sinyal fluoresens. Klona mAb 4-2D, 4-4F, dan 2-7A diuji terhadap protein NS1 native dari DENV1, DENV2, DENV3, dan DENV4, dan ketiga mAb tersebut mampu mengenali secara spesifik protein NS1 dan tidak bereaksi terhadap protein virus yang lain. Terdapat reaktivitas silang dengan 3 serotipe lainnya yang mengindikasikan bahwa mAb yang diujikan mengenali epitop lestari antigen NS1. Analisis prediksi epitop NS1 juga dilakukan secara in silico terhadap beberapa strain DENV lainnya. Namun, studi lebih lanjut mengenai pemetaan epitop dan afinitas pengikatan antigen-antibodi perlu dilakukan untuk menentukan mAb yang paling potensial sebagai bahan baku kit diagnostik.

---

Dengue DENV is a mosquito borne infection disease which its manifestation can be lead to a lethal dengue hemorrhagic fever DHF and or dengue shock syndrome DSS . In Indonesia, DHF has been endemic and the disease occurs throughout the year. Non structural 1 NS1 protein of DENV is known to be a biomarker in dengue diagnosis since the protein is abundantly circulating in the blood during acute phase of the disease. The aim of this study to develop monoclonal antibodies mAbs derived from DENV3 to detect NS1. Hybridoma mAb producing cells were obtained by fusing B cells from an immunized mice with NS1 antigen expressed on CHO K1 cells, with PAI myeloma cells. Hybridoma selection with indirect ELISA showed 16 clones that could be potentially produce anti NS1 antibodies.

Seven up to sixteen clones were selected to be characterized by IFA against recombinant NS1 antigen and the result showed 6 clones produce fluorescence signals. Clones mAb 4 2D, 4 4F, and 2 7A were tested against native NS1 proteins from DENV1, DENV2, DENV3, and DENV4, and these mAbs were able to recognize specifically NS1 protein and did not react against other viral proteins. There is a cross reactivity within 3 other serotypes which initially indicate that mAbs recognizes the conserved epitopes determinant of the NS1 antigen. Epitopes prediction analysis was also performed in silico against several others DENV strains. However, further studies of epitope mapping and antigen antibody binding affinity are necessary to determine the most potential mAbs for diagnostic tools. "